Get In Touch
Xeraya Capital Sdn Bhd
26.03–26.08, G Tower
#199 Jalan Tun Razak, KL
xeraya@xeraya.com
+603 2381 8700
Submit a Proposal
proposal@xeraya.com

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes?

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic ControlTM Product Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us – and rewrite the destiny of millions of people living with the disease.

Highlight

Foghorn's precision therapeutic candidates remodel the shape of DNA to tackle disease.

  • Founded

    2015

  • Partnered

    2020

  • IPO

    2020 (FHTX)

View Website
Let's talk

Are you the next big thing?

We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!

Back